CY1124944T1 - Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων - Google Patents

Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων

Info

Publication number
CY1124944T1
CY1124944T1 CY20221100087T CY221100087T CY1124944T1 CY 1124944 T1 CY1124944 T1 CY 1124944T1 CY 20221100087 T CY20221100087 T CY 20221100087T CY 221100087 T CY221100087 T CY 221100087T CY 1124944 T1 CY1124944 T1 CY 1124944T1
Authority
CY
Cyprus
Prior art keywords
antibodies
antigen binding
certain embodiments
weak
human
Prior art date
Application number
CY20221100087T
Other languages
English (en)
Inventor
Eric Smith
Lauric Haber
Robert Babb
Gang Chen
Douglas Macdonald
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1124944T1 publication Critical patent/CY1124944T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα εφεύρεση παρέχει αντισώματα που δεσμεύονται με το CD3 με ασθενή ή μη ανιχνεύσιμη συγγένεια δέσμευσης, και μεθόδους χρήσης αυτών. Σύμφωνα με ορισμένους τρόπους υλοποίησης, τα αντισώματα της εφεύρεσης δεσμεύουν ανθρώπινο CD3 με ασθενή συγγένεια και επάγουν τον πολλαπλασιασμό ανθρώπινων Τ κυττάρων και επομένως επάγουν τη μεσολαβούμενη από Τ κύτταρα θανάτωση κυττάρων όγκου με υψηλή αποτελεσματικότητα. Σύμφωνα με ορισμένους τρόπους υλοποίησης, η παρούσα εφεύρεση παρέχει αμφιειδικά μόρια δέσμευσης αντιγόνου που περιλαμβάνουν ένα πρώτο τομέα δέσμευσης αντιγόνου που δεσμεύει ειδικά ανθρώπινο CD3 με ασθενή ή μη ανιχνεύσιμη συγγένεια δέσμευσης σε μια in vitro δοκιμασία, και ένα δεύτερο μόριο δέσμευσης αντιγόνου που δεσμεύει ειδικά ανθρώπινο αντιγόνο που σχετίζεται με όγκο. Σε ορισμένους τρόπους υλοποίησης, τα αμφιειδικά μόρια δέσμευσης αντιγόνου της παρούσας εφεύρεσης έχουν την ικανότητα αναστολής της ανάπτυξης όγκων που εκφράζουν το αντιγόνο στόχο, όπως PSMA. Τα αντισώματα και τα αμφιειδικά μόρια δέσμευσης αντιγόνου της εφεύρεσης είναι χρήσιμα για τη θεραπευτική αντιμετώπιση νόσων και διαταραχών όπου μια αυξορρυθμισμένη ή επαγόμενη στοχευμένη ανοσοαπόκριση είναι επιθυμητή και/ή θεραπευτικά επωφελής. Για παράδειγμα, τα αντισώματα της εφεύρεσης είναι χρήσιμα για τη θεραπευτική αντιμετώπιση διάφορων καρκίνων ή άλλων νόσων όπου δικαιολογείται η ανοσοθεραπεία, δηλ. η ανοσοδιαμόρφωση δραστικών κυττάρων.
CY20221100087T 2015-09-23 2022-02-02 Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων CY1124944T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222605P 2015-09-23 2015-09-23
PCT/US2016/053525 WO2017053856A1 (en) 2015-09-23 2016-09-23 Optimized anti-cd3 bispecific antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CY1124944T1 true CY1124944T1 (el) 2023-01-05

Family

ID=57130447

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100087T CY1124944T1 (el) 2015-09-23 2022-02-02 Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων

Country Status (28)

Country Link
US (2) US20180355038A1 (el)
EP (1) EP3353212B1 (el)
JP (3) JP7023231B2 (el)
KR (1) KR20180050412A (el)
CN (1) CN108290951B (el)
AU (1) AU2016325630B2 (el)
BR (1) BR112018005445A2 (el)
CA (1) CA2999385A1 (el)
CY (1) CY1124944T1 (el)
DK (1) DK3353212T3 (el)
EA (1) EA201890785A1 (el)
ES (1) ES2901133T3 (el)
HK (1) HK1258304A1 (el)
HR (1) HRP20220133T8 (el)
HU (1) HUE057683T2 (el)
IL (1) IL258036B (el)
LT (1) LT3353212T (el)
MA (1) MA42935B1 (el)
MD (1) MD3353212T2 (el)
MX (1) MX2018003403A (el)
MY (1) MY195059A (el)
PL (1) PL3353212T3 (el)
PT (1) PT3353212T (el)
RS (1) RS62859B1 (el)
SI (1) SI3353212T1 (el)
TW (2) TWI783914B (el)
WO (1) WO2017053856A1 (el)
ZA (1) ZA201801673B (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3699198A1 (en) 2014-11-17 2020-08-26 Regeneron Pharmaceuticals, Inc. Methods for tumor treatment using cd3xcd20 bispecific antibody
JP6773679B2 (ja) 2015-03-30 2020-10-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｆｃガンマ受容体に対する結合が低下した重鎖定常領域
MX2017015011A (es) * 2015-05-28 2018-03-23 Genentech Inc Ensayo a base de celulas para detectar homodimeros anti-cd3.
TW202340452A (zh) 2015-08-04 2023-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20180134894A (ko) 2016-04-20 2018-12-19 리제너론 파마슈티칼스 인코포레이티드 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법
BR112018071283A2 (pt) 2016-04-20 2019-02-12 Regeneron Pharma célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, método, e, método para produção de uma proteína de ligação a antígeno.
PL3515487T3 (pl) * 2016-09-23 2024-01-15 Regeneron Pharmaceuticals, Inc. Dwuswoiste przeciwciała anty-muc16-cd3 oraz koniugaty przeciwciało anty-muc16 - lek
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
CA3068056A1 (en) * 2017-06-22 2018-12-27 Development Center For Biotechnology Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in cancer therapy
EA039842B1 (ru) * 2017-09-14 2022-03-18 Ридженерон Фармасьютикалз, Инк. Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство
US10865236B2 (en) * 2017-09-29 2020-12-15 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
MX2020006715A (es) * 2017-12-27 2020-08-20 Teneobio Inc Anticuerpos especificos del heterodimero de cd3-delta/epsilon.
TW202005985A (zh) * 2018-06-21 2020-02-01 美商再生元醫藥公司 用雙特異性抗ＣＤ３ｘＭＵＣ１６抗體及抗ＰＤ－１抗體治療癌症的方法
MA52970A (fr) 2018-06-21 2021-04-28 Regeneron Pharma Anticorps anti-psma x anti-cd28 bispécifiques et leurs utilisations
SG11202013138RA (en) 2018-07-02 2021-01-28 Amgen Inc Anti-steap1 antigen-binding protein
JP7319348B2 (ja) 2018-07-19 2023-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用
JP7402223B2 (ja) 2018-08-23 2023-12-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｆｃイプシロン－ｒ１アルファ（ｆｃｅｒ１ａ）抗体、ｆｃｅｒ１ａおよびｃｄ３に結合する二重特異性抗原結合分子、ならびにそれらの使用
JP2021535142A (ja) 2018-08-31 2021-12-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略
US20210340273A1 (en) 2018-10-11 2021-11-04 Inhlbrx, inc. 5t4 single domain antibodies and therapeutic compositions thereof
US20210380679A1 (en) 2018-10-11 2021-12-09 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
WO2020077257A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
WO2020076970A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
WO2020052692A2 (en) * 2018-12-04 2020-03-19 Novartis Ag Binding molecules against cd3 and uses thereof
US20220242953A1 (en) * 2018-12-07 2022-08-04 Jiangsu Hengrui Medicine Co., Ltd. Cd3 antibody and pharmaceutical use thereof
CN113166268A (zh) 2018-12-19 2021-07-23 瑞泽恩制药公司 双特异性抗muc16 x抗cd28抗体以及其用途
CA3124168A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
BR112021018442A2 (pt) 2019-03-22 2022-01-11 Regeneron Pharma Anticorpos multiespecíficos egfr x cd28
CA3139827A1 (en) * 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021030680A1 (en) 2019-08-15 2021-02-18 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
CN110551222B (zh) * 2019-08-27 2023-06-06 重庆市畜牧科学院 一种新型双功能抗体及其用途
EP4069373A1 (en) 2019-12-06 2022-10-12 Regeneron Pharmaceuticals, Inc. Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
CA3217738A1 (en) 2021-05-05 2022-05-04 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
WO2023097219A2 (en) * 2021-11-24 2023-06-01 Adimab, Llc Anti-idiotype antibodies
TW202346337A (zh) 2022-03-29 2023-12-01 美商恩格姆生物製藥公司 Ilt3及cd3結合劑以及其使用方法
WO2023201226A1 (en) 2022-04-11 2023-10-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN114685675B (zh) * 2022-04-27 2023-02-03 深圳市汉科生物工程有限公司 双特异性抗体及其在治疗癌症中的用途
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024077044A1 (en) 2022-10-05 2024-04-11 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024081180A1 (en) 2022-10-10 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1487487A2 (en) * 2001-09-28 2004-12-22 Elusys Therapeutics, Inc. Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules
US7820166B2 (en) 2002-10-11 2010-10-26 Micromet Ag Potent T cell modulating molecules
DE602004025101D1 (de) 2003-05-31 2010-03-04 Micromet Ag Humane anti-humane cd3-bindungsmoleküle
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2010054212A1 (en) * 2008-11-06 2010-05-14 Alexion Pharmaceuticals, Inc. Engineered antibodies with reduced immunogenicity and methods of making
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2496600A1 (en) 2009-11-04 2012-09-12 Fabrus LLC Methods for affinity maturation-based antibody optimization
TR201906650T4 (tr) 2010-02-08 2019-05-21 Regeneron Pharma Ortak hafif zincirli fare.
PL3339323T3 (pl) 2010-08-12 2020-05-18 Eli Lilly And Company Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania
RU2605390C2 (ru) * 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
RU2014153674A (ru) * 2012-06-05 2016-07-27 Регенерон Фармасьютикалз, Инк. Способ получения полностью человеческих биспецифических антител с применением общей легкой цепи
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
NZ630563A (en) * 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
KR20150064068A (ko) * 2012-10-08 2015-06-10 로슈 글리카트 아게 2개의 Fab 단편을 포함하는 FC-부재 항체 및 이용 방법
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CA2925677A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها

Also Published As

Publication number Publication date
MA42935A (fr) 2018-08-01
MA42935B1 (fr) 2022-02-28
AU2016325630B2 (en) 2022-11-17
HRP20220133T1 (hr) 2022-04-15
AU2016325630A1 (en) 2018-04-26
CN108290951B (zh) 2022-04-01
TW201726713A (zh) 2017-08-01
WO2017053856A1 (en) 2017-03-30
PL3353212T3 (pl) 2022-03-28
ZA201801673B (en) 2022-12-21
RS62859B1 (sr) 2022-02-28
DK3353212T3 (da) 2021-12-20
CN108290951A (zh) 2018-07-17
LT3353212T (lt) 2021-12-27
IL258036B (en) 2022-09-01
MY195059A (en) 2023-01-05
TW202241514A (zh) 2022-11-01
JP2018537516A (ja) 2018-12-20
EP3353212B1 (en) 2021-11-03
TWI783914B (zh) 2022-11-21
SI3353212T1 (sl) 2022-01-31
ES2901133T3 (es) 2022-03-21
US20180355038A1 (en) 2018-12-13
JP7023231B2 (ja) 2022-02-21
MX2018003403A (es) 2018-05-28
EP3353212A1 (en) 2018-08-01
TWI784917B (zh) 2022-11-21
MD3353212T2 (ro) 2022-03-31
US20210253701A1 (en) 2021-08-19
HRP20220133T8 (hr) 2022-05-13
JP2022064886A (ja) 2022-04-26
HK1258304A1 (zh) 2019-11-08
HUE057683T2 (hu) 2022-05-28
EA201890785A1 (ru) 2018-10-31
JP2023154021A (ja) 2023-10-18
BR112018005445A2 (pt) 2018-10-09
IL258036A (en) 2018-05-31
CA2999385A1 (en) 2017-03-30
KR20180050412A (ko) 2018-05-14
PT3353212T (pt) 2022-01-05

Similar Documents

Publication Publication Date Title
CY1124944T1 (el) Βελτιστοποιημενα αμφιειδικα αντισωματα αντι-cd3 και χρησεις αυτων
CY1124090T1 (el) Συνθεσεις αντισωματων για τη θεραπεια ογκων
CY1124747T1 (el) Ανθρωπινα αντισωματα σε pd-1
CY1124437T1 (el) Ανθρωπινα αντισωματα κατα toy pd-l1
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
CY1120471T1 (el) Αντισωματα κατα του cd70
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CY1119219T1 (el) Anti-ceacam5 αντισωματα και χρησεις αυτων
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
NZ754730A (en) Anti-icos agonist antibodies and uses thereof
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
EA202191580A1 (ru) Биспецифичные антитела анти-cd28 x анти-cd22 и их применение
EA201491686A1 (ru) Мультиспецифические антигенсвязывающие молекулы и их применения
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
CY1123743T1 (el) Αντισωμα igf-ir και χρηση του ως ουσια-οχημα διευθυνσιοδοτησης για την αγωγη του καρκινου
EA202090303A3 (ru) Композиции антител для лечения опухолей
EA202190089A1 (ru) Биспецифичные антитела анти-psma x анти-cd28 и их применения
EA201992136A1 (ru) Антитела против pd-l1
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения
EA202192306A3 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
AR099798A1 (es) Métodos y composiciones de anticuerpos para el tratamiento de tumores